Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,784Revenue (TTM) $M43.2Net Margin (%)-453.4Altman Z-Score-4.4
Enterprise Value $M1,851EPS (TTM) $-0.9Operating Margin %-342.0Piotroski F-Score4
P/E(ttm)--Beneish M-Score-3.8Pre-tax Margin (%)-453.3Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio3.3Cash flow > EarningsY
Price/Sales38.85-y EBITDA Growth Rate %--Current Ratio3.4Lower Leverage y-yN
Price/Free Cash Flow37.2y-y EBITDA Growth Rate %--ROA % (ttm)-57.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M229ROIC % (ttm)-212.8Gross Margin Increase y-yN

Gurus Latest Trades with EXEL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
EXELCharles Brandes 2016-03-31 Sold Out $3.64 - $5.64
$ 7.8084%Sold Out0
EXELCharles Brandes 2015-12-31 Reduce$4.79 - $6.33
$ 7.8040%Reduce -44.88%14,000
EXELCharles Brandes 2015-06-30 Buy $2.57 - $4.03
$ 7.80141%New holding25,400
EXELFirst Eagle Investment 2014-06-30 Sold Out -0.0038%$3.22 - $3.8
$ 7.80126%Sold Out0
EXELFirst Eagle Investment 2014-03-31 Reduce-0.01%$3.38 - $8.24
$ 7.8014%Reduce -65.91%400,000
EXELFirst Eagle Investment 2012-09-30 Add0.02%$4.28 - $6.45
$ 7.8047%Add 422.58%1,175,800
EXELFirst Eagle Investment 2012-03-31 Add$4.49 - $6.47
$ 7.8052%Add 125.00%225,000
EXELFirst Eagle Investment 2011-12-31 Buy $3.95 - $7.81
$ 7.8056%New holding100,000
EXELCarl Icahn 2011-09-30 Sold Out -0.43%$5.5 - $9.22
$ 7.806%Sold Out0
EXELFirst Eagle Investment 2011-03-31 Sold Out -0.01%$7.22 - $12.45
$ 7.80-22%Sold Out0
EXELFirst Eagle Investment 2010-12-31 Buy 0.01%$3.98 - $9.08
$ 7.8038%New holding280,000
EXELFirst Eagle Investment 2009-12-31 Sold Out -0.02%$5.33 - $8
$ 7.8014%Sold Out0
EXELFirst Eagle Investment 2009-09-30 Buy 0.02%$4.4 - $6.99
$ 7.8038%New holding274,700
EXELFirst Eagle Investment 2009-06-30 Sold Out -0.01%$4.16 - $5.55
$ 7.8060%Sold Out0
EXELFirst Eagle Investment 2009-03-31 Reduce$4.32 - $5.85
$ 7.8063%Reduce -25.67%144,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

EXEL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

EXEL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
WILLSEY LANCEDirector 2016-05-11Buy60,000$4.9756.94view
WILLSEY LANCEDirector 2015-12-11Buy100,000$4.8959.51view
Lamb PeterEVP, Discovery Research & CSO 2015-10-16Sell51,549$5.834.48view
Lamb PeterEVP, Discovery Research & CSO 2015-10-13Sell300,876$5.8433.56view
MARCHESI VINCENT TDirector 2014-09-17Buy20,000$1.71356.14view
WILLSEY LANCEDirector 2013-08-29Buy10,000$5.1551.46view
MARCHESI VINCENT TDirector 2012-12-20Buy4,000$4.6866.67view
MARCHESI VINCENT TDirector 2012-12-19Buy6,000$4.7265.25view
Schwab GiselaEVP and Chief Medical Officer 2012-12-10Buy25,000$4.3977.68view
MARCHESI VINCENT TDirector 2012-06-14Sell7,000$5.1352.05view

Quarterly/Annual Reports about EXEL:

News about EXEL:

Articles On GuruFocus.com
The Best-Performing Non-S&P Stocks of 2015 Dec 30 2015 
5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 

More From Other Websites
Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining... Jun 29 2016
Explosive Stocks Under $10 Jun 28 2016
Biotech Stock Bounce Picks Up Momentum Jun 23 2016
'Mad Money' Lightning Round: I'm Sticking With Wells Fargo Jun 15 2016
Research Coverage Scans Stocks on the Biotechnology Industry for Today Jun 08 2016
Exelixis Up on Positive Kidney Cancer Data on Cabometyx Jun 07 2016
Exelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher Jun 07 2016
Here’s Why These Five Stocks Are Surging Today Jun 06 2016
Exelixis (EXEL) Stock Gains on Positive Trial Results for Kidney Cancer Treatment Jun 06 2016
Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of... Jun 06 2016
Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of... Jun 06 2016
Exelixis's stock surges after positive results from trial of kidney cancer treatment Jun 06 2016
Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of... Jun 06 2016
Exelixis Inc Investor/Analyst Briefing to Review Cabozantinib Data at the American Society of... Jun 05 2016
Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX™ (Cabozantinib) Tablets... Jun 05 2016
Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination... Jun 05 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)